| Literature DB >> 35805888 |
Alfredo Torres1,2, Sheilah Vivanco1, Francisca Lavín1, Cristián Pereda3, Alexey Chernobrovkin4, Alejandra Gleisner3, Marcela Alcota2, Milton Larrondo5, Mercedes N López3,6, Flavio Salazar-Onfray3,6, Roman A Zubarev4, Fermín E González1,2,6.
Abstract
Damage-associated molecular patterns (DAMPs) play a critical role in dendritic cells (DCs) ability to trigger a specific and efficient adaptive immune response for different physiological and pathological scenarios. We have previously identified constitutive DAMPs (HMGB1 and Calreticulin) as well as new putative inducible DAMPs such as Haptoglobin (HP), from a therapeutically used heat shock-conditioned melanoma cell lysate (called TRIMEL). Remarkably, HP was shown to be the most abundant protein in the proteomic profile of heat shock-conditioned TRIMEL samples. However, its relative contribution to the observed DCs phenotype has not been fully elucidated. Human DCs were generated from monocytes isolated from PBMC of melanoma patients and healthy donors. DC lineage was induced with rhIL-4 and rhGM-CSF. After additional stimulation with HP, the proteome of these HP-stimulated cells was characterized. In addition, DCs were phenotypically characterized by flow cytometry for canonical maturation markers and cytokine production. Finally, in vitro transmigration capacity was assessed using Transwell plates. Our results showed that the stimulation with HP was associated with the presence of exclusive and higher relative abundance of specific immune-; energy production-; lipid biosynthesis-; and DAMPs-related proteins. Importantly, HP stimulation enhanced the expression of specific DC maturation markers and pro-inflammatory and Th1-associated cytokines, and an in vitro transmigration of primary human DCs. Taken together, these data suggest that HP can be considered as a new inducible DAMP with an important role in in vitro DC activation for cancer immunotherapy.Entities:
Keywords: DAMPs; dendritic cells; haptoglobin; melanoma cell lysates
Mesh:
Substances:
Year: 2022 PMID: 35805888 PMCID: PMC9266681 DOI: 10.3390/ijms23136882
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1Qualitative and quantitative proteomic comparison of AM, HP-, and TRIMEL-stimulated cells. (A) The Venn diagram of the identified proteins shows that a total of 2395 proteins were identified. In addition, 2263 proteins were present in the three studied conditions. Furthermore, 22 proteins were simultaneously found in HP- and TRIMEL-stimulated cells; 64 in HP and AM; and 26 in TRIMEL and AM cells. Nine proteins were exclusively identified in HP-stimulated cells, four in TRIMEL-stimulated cells, and seven in AM cells. (B) Volcano Scatter Plot of the proteins with the highest abundance (≥2 fold-change) from AM vs. HP, and (C) AM vs. TRIMEL. The plots were constructed based on the variation in the fold change of each protein (Log2) and the p-value (−Log10) when comparing both groups. (D) Representation of the exclusive and more abundant (≥2 times) proteins between HP and AM cells. In addition, 2327 proteins were present in both groups. Of them, 52 proteins were more abundant in HP samples and 31 in AM and 31 proteins were only identified in HP and 33 in AM; (E) representation of the exclusive and more abundant proteins between TRIMEL and AM cells. A total of 2289 proteins were found in both groups. Twenty-one proteins were more abundant in TRIMEL samples and 73 in AM cells. Twenty-six proteins were exclusively identified in TRIMEL-stimulated cells and 71 in AM cells.
Currently known functions of the 83 selected gene-proteins regulated by HP (showed in Figure 1C). The list of proteins was previously filtered by exclusivity or abundance (log2(Fold Change)) > 1, when comparing HP vs. AM.
| Gene | ID (Uniprot) | Full Name (Uniprot) | Protein Subgroup | Function (Gene Ontology) |
|---|---|---|---|---|
| TAP2 | A0A0G2JLV0 | Antigen peptide transporter 2 | E | i. Antigen processing and presentation of endogenous peptide antigen via MHC class I |
| FDXR | A0A0A0MTN9 | NADPH:adrenodoxin oxidoreductase, mitochondrial | E | NADPH-adrenodoxin reductase activity |
| NDUFA6 | R4GN43 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 6 | E | i. NADH dehydrogenase (ubiquinone) activity |
| TJP2 | A0A1B0GTW1 | Tight junction protein ZO-2 | E | i. Cell adhesion molecule binding |
| SAE1 | M0QX65 | SUMO-activating enzyme subunit 1 | E | Regulation of actin cytoskeleton organization |
| SLAMF7 | B4DW98 | SLAM family member 7 | E | Identical protein binding |
| BAIAP2 | B4DWA1 | Brain-specific angiogenesis inhibitor 1-associated protein 2 | E | Regulation of actin cytoskeleton and membrane organization |
| SLC25A20 | C9JPE1 | Mitochondrial carnitine/acylcarnitine carrier protein | E | Acyl carnitine transmembrane transporter activity |
| KRT14 | CON_P02533 | Keratin, type I cytoskeletal 14 | E | i. Keratin filament binding, |
| BZW2 | Q75MG1 | Basic leucine zipper and W2 domain-containing protein 2 | E | Cadherin binding |
| ACADS | E9PE82 | Short-chain specific acyl-CoA dehydrogenase, mitochondrial | E | i. Acyl-CoA; butiryl-CoA dehydrogenase activity, |
| CRYAB | E9PR44 | Alpha-crystallin B chain | E | i. Amyloid-beta; identical protein; metal ion; microtubule; and unfolded protein binding |
| CD1C | H0Y6Y6 | T-cell surface glycoprotein CD1c | E | i. Endogenous; exogenous lipid antigen binding, |
| CLUH | I3L2B0 | Clustered mitochondria protein homolog | E | mRNA binding |
| SLC16A3 | O15427 | Monocarboxylate transporter 4 | E | Lactate and monocarboxylic transmembrane acid transport |
| AK1 | Q5T9B7 | Adenylate kinase isoenzyme 1 | E | Adenylate kinase activity and ATP binding |
| SLC25A4 | P12235 | ADP/ATP translocase 1 | E | i. ATP:ADP antiporter activity |
| ACADSB | P45954-2 | Short/branched chain specific acyl-CoA dehydrogenase | E | i. Short-branched-chain-and acyl-CoA dehydrogenase activity |
| RECQL | P46063 | ATP-dependent DNA helicase Q1 | E | DNA unwinding involved in DNA replication and repair |
| LIG3 | P49916-4 | DNA ligase 3 | E | i. ATP; DNA; zinc ion binding, |
| MFAP1 | P55081 | Microfibrillar-associated protein 1 | E | RNA binding |
| TUBB2A | Q13885 | Tubulin beta-2A chain | E | Microtubule cytoskeleton organization |
| MORC3 | Q14149 | MORC family CW-type zinc finger protein 3 | E | Innate immune response, protein stabilization and maintenance of protein location in nucleus |
| SMEK1 | Q6IN85-2 | Serine/threonine-protein phosphatase 4 regulatory subunit 3A | E | Regulatory subunit of SMEK1 |
| ATL2 | Q8NHH9-5 | Atlastin-2 | E | i. GTP; identical protein binding |
| DCP1A | Q9NPI6-2 | mRNA-decapping enzyme 1A | E | i. mRNA; kinesin and identical protein binding |
| ACSS2 | Q9NR19 | Acetyl-coenzyme A synthetase, cytoplasmic | E | i. Lipid biosynthetic process |
| CHMP5 | Q9NZZ3 | Charged multivesicular body protein 5 | E | Vacuolar transport, lysosome organization and negative regulation of cell death |
| ATXN10 | Q9UBB4-2 | Ataxin-10 | E | Cilium assembly and nervous system development |
| WDR37 | Q9Y2I8 | WD repeat-containing protein 37 | E | N/A |
| COA3 | Q9Y2R0 | Cytochrome c oxidase assembly factor 3 homolog | E | Mitochondrial cytochrome c oxidase assembly |
| HLA-DRB1 | Q9GIY3 | HLA class II histocompatibility antigen, DRB1-14 beta chain | MA | MHC class II receptor activity |
| CCDC58 | C9JQ41 | Coiled-coil domain-containing protein 58 | MA | N/A |
| HLA-DQB1 | A2AAZ0 | HLA class II histocompatibility antigen, DQ beta 1 chain | MA | MHC class II receptor activity |
| CCL3 | P10147 | C-C motif chemokine 3 | MA | Chemoattractant and protein kinase activity |
| HLA-B | P30493 | HLA class I histocompatibility antigen, B-55 alpha chain | MA | Peptide antigen and signaling receptor binding |
| SLC39A7 | Q92504 | Zinc transporter SLC39A7 | MA | Zinc ion transmembrane transporter activity |
| FADS2 | O95864 | Fatty acid desaturase 2 | MA | i. Oxidoreductase activity |
| FBP2 | O00757 | Fructose-1,6-bisphosphatase isozyme 2 | MA | i. Catalytic and hydrolase activity |
| HLA-DRB5 | Q30154 | HLA class II histocompatibility antigen, DR beta 5 chain | MA | MHC class II protein complex binding |
| ITGAE | P38570 | Integrin alpha-E | MA | Integrin and metal ion binding |
| PCCB | F8WBI9 | Propionyl-CoA carboxylase beta chain, mitochondrial | MA | Ligase activity |
| DHX38 | Q92620 | Pre-mRNA-splicing factor ATP-dependent RNA helicase PRP16 | MA | i. RNA and nucleic acid binding |
| HMGCS1 | Q01581 | Hydroxymethylglutaryl-CoA synthase | MA | Protein homodimerization activity |
| PTPMT1 | Q8WUK0-2 | Phosphatidylglycerophosphatase and protein-tyrosine phosphatase 1 | MA | Protein tyrosine/serine/threonine phosphatase activity |
| HLA-C | A2AEA2 | HLA class I histocompatibility antigen, Cw-7 alpha chain | MA | Peptide antigen binding |
| HLA-B | P30685 | HLA class I histocompatibility antigen, B-35 alpha chain | MA | Peptide antigen and signaling receptor binding |
| RNF17 | Q9BXT8-4 | RING finger protein 17 | MA | Metal ion and protein binding |
| GNPDA1 | P46926 | Glucosamine-6-phosphate isomerase 1 | MA | Hydrolase and deaminase activity |
| HLA-B | Q04826 | HLA class I histocompatibility antigen, B-40 alpha chain | MA | Peptide antigen and signaling receptor binding |
| DEFA3 | P59666 | Neutrophil defensin 3 | MA | Protein homodimerization activity |
| PPCS | Q9HAB8-2 | Phosphopantothenate--cysteine ligase | MA | Protein homodimerization activity |
| DCD | P81605 | Dermcidin; Survival-promoting peptide; DCD-1 | MA | Peptidase activity |
| ATP5E | Q5VTU8 | ATP synthase subunit epsilon, mitochondrial | MA | Proton-transporting ATP synthase activity |
| DHRS4 | Q9BTZ2-8 | Dehydrogenase/reductase SDR family member 4 | MA | Carbonyl reductase (NADPH) activity |
| HDDC3 | H0YNP9 | Guanosine-3,5-bis(diphosphate) 3-pyrophosphohydrolase MESH1 | MA | Metal ion binding |
| SETD3 | Q86TU7 | Histone-lysine N-methyltransferase setd3 | MA | Transcription coactivator and histone methyltransferase activity |
| POLE3 | Q9NRF9 | DNA polymerase epsilon subunit 3 | MA | Chromatin DNA binding |
| FDPS | P14324-2 | Farnesyl pyrophosphate synthase | MA | i. Transtransferase activity |
| UBE2G2 | P60604 | Ubiquitin-conjugating enzyme E2 G2 | MA | Ubiquitin conjugating enzyme activity |
| KRT1 | P04264 | Keratin, type II cytoskeletal 1 | MA | i. Structural constituent of skin epidermis |
| HLA-DRB1 | Q29974 | HLA class II histocompatibility antigen, DRB1-16 beta chain | MA | MHC class II protein complex binding |
| RDH11 | Q8TC12-3 | Retinol dehydrogenase 11 | MA | Cellular detoxification of aldehyde |
| CHMP2A | O43633 | Charged multivesicular body protein 2a | MA | Protein binding |
| AZGP1 | P25311 | Zinc-alpha-2-glycoprotein | MA | Protein transmembrane transporter activity |
| AGPAT3 | Q9NRZ7-2 | 1-acyl-sn-glycerol-3-phosphate acyltransferase gamma | MA | Phospholipid biosynthetic process |
| DAD1 | F5GXX5 | Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 | MA | Enzyme activator activity |
| C11orf54 | E9PR95 | Ester hydrolase C11orf54 | MA | Metal ion binding |
| CD1A | P06126 | T-cell surface glycoprotein CD1a | MA | Protein and lipid antigen binding |
| KRT10 | CON_P13645 | Keratin, type I cytoskeletal 10 | MA | i. Structural constituent of skin epidermis |
| CYP51A1 | A0A0C4DFL7 | Lanosterol 14-alpha demethylase | MA | i. Heme and iron ion binding |
| LSM5 | B8ZZF8 | U6 snRNA-associated Sm-like protein LSm5 | MA | mRNA splicing |
| DTX3L | Q8TDB6 | E3 ubiquitin-protein ligase DTX3L | MA | i. Ubiquitin protein ligase activity |
| GABARAP | H6UMI1 | Gamma-aminobutyric acid receptor-associated protein | MA | i. Autophagosome assembly |
| BAG5 | Q9UL15 | BAG family molecular chaperone regulator 5 | MA | Protein kinase and chaperone binding |
| ABCD3 | P28288-2 | ATP-binding cassette sub-family D member 3 | MA | Protein binding |
| NUTF2 | P61970 | Nuclear transport factor 2 | MA | i. Small GTPase binding |
| RBM10 | A0A0A0MR66 | RNA-binding protein 10 | MA | RNA; miRNA; metal ion and protein binding |
| TIMM8A | O60220 | Mitochondrial import inner membrane translocase subunit Tim8A | MA | Metal ion and protein binding |
| SAMSN1 | Q9NSI8 | SAM domain-containing protein SAMSN-1 | MA | Phosphotyrosine residue and RNA binding |
| PTRHD1 | Q6GMV3 | Putative peptidyl-tRNA hydrolase PTRHD1 | MA | Hydrolase activity |
| KRT9 | P35527 | Keratin, type I cytoskeletal 9 | MA | Structural constituent of cytoskeleton |
| HSPA6 | P17066 | Heat shock 70 kDa protein 6 | MA | i. Stress response |
E, exclusive proteins (n = 31); MA, more abundant proteins (n = 52).
Figure 2Protein–protein interaction network and fold change of relevant proteins in HP- and TRIMEL-stimulated cells. (A) Protein interactome of exclusive and more abundant proteins in HP-stimulated cells compared with AM. Interactome of proteins selected from a differentiated panel of 83 proteins, of which 31 are exclusive and 52 are in greater abundance (≥2 fold-change), shows proteins related to antigen processing and presentation (red), energy production (green) and lipid biosynthesis (yellow). In addition, proteins associated with cancer development (cyan shadow), changes in cell shape and cell migration (grey shadow), and proteins with DAMP functions (orange shadow) were also identified. Proteins were found more abundant considering a cutoff p < 0.01 or abs (log2 (FC)) > 1; (B) comparison of TRIMEL/AM and HP/AM fold-changes of selected proteins. In both TRIMEL- and HP-stimulated cells, there were several proteins with a higher abundance regarding AM condition. In the TRIMEL group, the most abundant proteins were DEFA1 (35.9 fold-change), HLA-DRV1 (27.93 fold-change) and SLC39A7 (8.14 fold-change), while, in the HP group, the most abundant proteins were: HLA-DRB1 (10.8 fold-change), HLA-DQB1 (9.03 fold-change) and CCL3 (8.4 fold-change). Confined cell migration related proteins were more abundant in the TRIMEL group compared with HP-stimulated cells. * p < 0.05.
Figure 3In vitro effects of HP on primary human monocyte-derived iDCs phenotype and cytokine production. DC lineage was induced with IL-4 (500 U/mL), and GM-CSF (800 U/mL) as previously described [18], before additional stimulation with HP and HS-MCL (TRIMEL) lysate as control. (A) gating strategy; (B) MHC-I, CD80, CD83 and CD86 expression in unstimulated cells (AM), TRIMEL-stimulated cells (50 μg/mL), and HP-stimulated cells (10 ng/mL); (C) percentage of MHC-I, CD80, CD83, and CD86 positive cells in AM, TRIMEL-stimulated cells (50 μg/mL), and HP-stimulated cells (0,1 and 10 ng/mL); (D) IL-12, TNF-α, IL-10, IL-6, and IL-8 secretion. The concentration of cytokines was analyzed in supernatants obtained from 24 h co-cultures of AM or HP-stimulated iDCs with CD-40L expressing fibroblast (1:1 ratio). * p < 0.05; ** p < 0.01.
Figure 4CCR7 expression and in vitro transmigration capability in HS-stimulated primary human iDCs. (A) Representative zebra plots showing the percentage of CCR7 positive cells in AM and HP-stimulated cells (1 and 10 ng/mL); (B) CCR7 expression in unstimulated cells (AM), TRIMEL-stimulated cells (50 μg/mL), and HP-stimulated cells (10 ng/mL); (C) percentage of CCR7 positive cells in AM, TRIMEL-stimulated cells (50 μg/mL), and HP-stimulated cells (0,1 and 10 ng/mL); (D) representative images from Transwell experiments of different conditions: AM, TRIMEL, INS, and HP in response to the canonical CCR7 ligand, the chemokine CCL19 (10 ng/mL) or AIM-V (negative control); (E) quantification of the in vitro transmigration of AM and stimulated cells with TRIMEL (50 μg/mL), Insulin (10 ng/mL), and HP (10 ng/mL). Data are expressed as a migration index, which is the ratio between the number of migrated cells towards CCL19 and the number of migrated cells towards the medium alone for each cell condition studied. * p < 0.05; ** p < 0.01; **** p < 0.0001.